Clinical Trial: I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

Brief Summary: I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors

Detailed Summary:

Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma.

Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide

Sponsor: Children's Hospital Medical Center, Cincinnati

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Children's Hospital Medical Center, Cincinnati

Dates:
Date Received: December 27, 2007
Date Started: January 1991
Date Completion:
Last Updated: August 24, 2009
Last Verified: January 2007